drugset
drugset / Trial / NCT06215521

A Study to Evaluate the Effect of Pirtobrutinib (LOXO-305) on QTc Interval in Healthy Participants

NCT06215521 ↗

Phase 1 Completed 31 enrolled Eli Lilly and Company Loxo Oncology, Inc. · collab
RandomizedCrossoverDouble-blindBasic science

Summary

The main purpose of this study is to assess the effect of Pirtobrutinib (LOXO-305) on the heart rate-corrected QT (QTc) interval and to conduct blood tests to measure how much pirtobrutinib (LOXO-305) is in the bloodstream and how the body handles and eliminates pirtobrutinib. The study will also evaluate the safety and tolerability of pirtobrutinib. The study will last up to 71 days, including screening.

Timeline

Start
2020-12-15
Primary completion
2021-03-31
Completion
2021-03-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Moxifloxacin Small molecule — Oral
Subject Pirtobrutinib Other / unclassified — Oral

Indications

No indication recorded.